Home / Top News / Merck shares fall despite saying cholesterol drug met primary goal in study

Merck shares fall despite saying cholesterol drug met primary goal in study


Merck said Tuesday its cholesterol drug Anacetrapib met its primary goal in a study, significantly reducing coronary heart disease.

Shares of the pharmaceutical company fell about 0.4 percent in morning trade, after spiking more than 3 percent in premarket trade.

Results of the study on 30,000 individuals will be presented on Aug. 29 at a European Society of Cardiology meeting.

Merck 2-day performance

Source: FactSet

Merck said in a press release that it plans to review the trial results with outside experts and will consider whether to file a new drug application with the U.S. Food and Drug Administration, among other regulatory agencies.

Merck shares are up nearly 12 percent year-to-date. Analysts said this month the results of this study would be the next major catalyst for the Dow Jones Industrial average member.

About admin

Check Also

39% of younger millennials say Covid-19 has them moving back home

Nearly 3 out of 4 younger millennials are concerned that the coronavirus pandemic will impact …